Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04840901 · ClinicalTrials.gov registry record · Phase 1
A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
NCT04840901: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT04840901 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 242 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04840901, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
Study Summary
The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.
Primary Outcome
PK: Cmax of Lebrikizumab
Interventions
- DRUG Lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2021-06-02 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 1 |
What the finished NCT04840901 record still lists
NCT04840901 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher).
The record links to 0 conditions, and to 1 intervention - of which Lebrikizumab is the first listed.
NCT04840901 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04840901 about?
NCT04840901 is a clinical study titled "A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants". The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS...
What is the current status of trial NCT04840901?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2021-06-02. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04840901?
The interventions under investigation include: Lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT04840901?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04840901's enrollment target sits among peer trials
242 194th of 2000 higher than 1,805 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI